Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sandrine d’Argouges
Observed names:
Sandrine d'Argouges,
Sandrine dÁrgouges
Institution:
Amgen (Germany)
Observed institution:
Amgen (Germany)
OpenAlex ID:
A5013370111
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct
2007
·
Christian Brandl
, Cornelia Haas
, et al.
·
Cancer Immunology Immunotherapy
·
148
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
2008
·
Sandrine d’Argouges
, Sandra Wissing
, et al.
·
Leukemia Research
·
83
Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release
2009
·
Maria Amann
, Sandrine dÁrgouges
, et al.
·
Journal of Immunotherapy
·
68
The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated
2011
·
Christine Plater-Zyberk
, Dave M. Lopes Estêvão
, et al.
·
Transplant Immunology
·
2
How useful are 3-month repeat-dose toxicology studies for the development of T cell engagers for oncology indications?
2025
·
Petra Lutterbuese
, Sandrine d’Argouges
, et al.
·
Regulatory Toxicology and Pharmacology
·
1
Show more works
View as search
Works count:
5
Citation count:
302
H-index:
3
I10-index:
3
Year
Topic
Type